In this study, we chose four ADAM17 variants located within the catalytic domain for analysis: three were found in colon cancer samples (E319G, E406X, M435I) and one in pancreatic cancer (P417Q), all of them resulting in an amino acid change or the introduction of an early stop codon. Here, ADAM17 is linked to pancreatic neoplasm.